| INTRODUC TI ON
Invasive fungal infections (IFI) of the Central Nervous System (IFI-CNS) and those of the Paranasal Sinuses (IFI-PS) are rare, lifethreatening infections in haematologic patients, and their management remains a challenge despite the availability of new diagnostic techniques and novel antifungal agents. [1] [2] [3] [4] [5] [6] [7] [8] There is a lack of recent epidemiologic studies with a proper number of cases reporting the outcome of haematologic patients with IFI involving CNS and PS, and therefore, the most appropriate diagnostic and therapeutic approach remain to be clearly defined. In fact, in the literature, we found only case reports or small retrospective studies, more often not recent. 1, [9] [10] [11] [12] [13] The most frequently reported pathogens were moulds and especially Aspergillus and Mucormycetes. 1, 2, 6, 14, 15 The therapeutic management of these infectious complications is still very complex and heterogeneous, and recent studies on the efficacy of new antimycotic drugs are limited so that there is no clear standard of care currently available. For these reasons, we decided to carry out a study providing an update on current epidemiology and outcome of IFI-CNS and IFI-PS occurring in haematological patients in recent years aiming to improve the knowledge and management of these serious and rare infectious complications. 
| PATIENTS AND ME THODS

| Definitions
Severe neutropenia was defined as a number of granulocytes (PMN) ≤500/mmc. Mild/moderate neutropenia was defined as PMN counts between 500 and 1500/mmc. Steroid therapy has been defined as the use of prednisone or prednisolone for at least 7 days at a dose of 25 mg/day or 1 mg/kg/day, respectively. Fever has been defined according to the IDSA guidelines as an increase in body temperature ≥38.3°C once or ≥38°C for more than 1 hour. 
16
In the case of a patient's death, the cause of death had to be specified as one of the following: (a) mycosis as primary cause, (b)
haematological disease as primary cause with concomitant mycosis, (c) haematological disease in the absence of mycosis, (d) other causes.
We considered IFI attributable mortality every death occurring without evidence of active haematological disease and attributable only to infection as a primary cause of death. Patients received steroid therapy in 61/89 cases (69%), and 13 patients (15%) had a history of diabetes.
| Statistical analysis
| Clinical manifestations and aetiology of IFI
The most common presenting symptoms were fever in 65% (58/89) 
| Aetiological agents
| Localisation of IFI
| Diagnosis of IFI
TA B L E 3 IFI-therapy, response and outcome
of IFI-CNS, and it was positive in 20/30 (67%) ( Table 2 ). Excisional surgery was performed in 26% of the cases (22/84), more often in patients with IFI-PS (33%) as compared to IFI-CNS (10%) (P = 0.028).
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| Antifungal therapy
The overall response rate (ORR) to treatment was 57% (with CR 34% and PR 23%), without significant differences between F I G U R E 1 (A) Overall Survival from IFI Diagnosis-All Cases. (B) OS from IFI Diagnosis-according to site (CNS or PS) the 2 cohorts ( Table 3 ). The ORR in the cases of Aspergillosis and Mucormycosis was 53% and 52%, respectively.
| Outcome
Median survival of the entire patient population was 3.5 months after the diagnosis of IFI (IFI-CNS 3,3 mths and IFI-PS 4,7 mths) with a 12-month OS probability of 32% ( Figure 1A ). The 12-month OS was 23% in IFI-CNS and 34% in IFI-PNS (Log-rank, P > 0.05) ( Figure 1B) . The overall mortality was 69% (61/89) without a significant difference between the two groups. The mortality rate for IFI as the primary cause (attributable mortality) was 33% (20/61 cases) while the mortality from haematological disease with IFI as a contributory factor was 44% (27/61) ( Table 3) .
Univariate and multivariate analysis of the variables potentially influencing the OS are shown in Table 4 . Analyses have been restricted to 66 IFI-CNS that received antimycotic treatment ( 
| D ISCUSS I ON
IFIs with localisation at CNS and PS are a rare and severe infectious complication in the course of haematological diseases. The diagnosis of such infectious complications can be complex because the symptoms and signs are not specific, indirect microbiology techniques are not validated on all biological fluids (i.e, CSF), and biopsy is often difficult in patients with underlying haematological malignancies. 1 In the cases of CNS or PS-IFI, the antifungal treatment is frequently associated with a poor efficacy and this is due both to the poor permeability of antifungal drugs in anatomical sites (such as CNS) and to the inability, in most cases, to integrate drug therapy with surgery.
1,9,12
Unfortunately, recent epidemiological studies involving large cohorts of haematological patients with IFI-CNS or IFI-PS are lacking and, We also confirm that IFI-CNS are frequently associated with concomitant involvement of other sites (for instance in the lung). In fact, isolated IFI-CNS forms accounted for only 25% of the cases in this study. This confirms the aetiopathogenic hypothesis that the IFI-CNS could originate from the haematogenous dissemination of an infection arising from another primary site (such as the lung). 1, 11, 19 In this study, a pulmonary IFI has preceded a CNS or PS localisation in 48% of cases.
TA B L E 4 Univariate and multivariate analyses of factors that influenced overall survival in 66 cases of IFI-CNS who received treatment
Therefore, in patients with pulmonary mycosis, the persistence of fever, despite a pulmonary improvement, or the onset of a headache or other neurological signs, such as diplopia, should never be underestimated. With regard to the diagnosis of IFIs, our data show that indirect methods of diagnosis are now commonly used including radiological examinations and biological markers such as GM, which represents a well consolidated diagnostic method. 1, 9, 12, [20] [21] [22] [23] [24] β-D-Glucan appears not to be widely used, both for blood and CSF. The histological diagnosis remains rarely used, even in the recent period of this study (histological diagnosis was made only in 29% of cases). In addition, it should be noted that, while diagnostic biopsy of PS was performed in 69% of cases, brain diagnostic biopsy was performed only in 10% of IFI-CNS and mainly in patients with a platelet count >100,000/mmc.
In our series of IFI-CNS, while serum GM was systematically performed, GM on CSF was tested in a limited percentage (42%) of cases, but in cases where this test was performed, it was positive and, therefore, informative in 67% of cases. This information underlines that the determination of GM in CSF can be useful in the diagnosis of CNSAspergillosis, and therefore, a diagnostic lumbar puncture should be encouraged in cases with a suspected CNS fungal infection. 1, 20, 25 On the other hand, we found that β-D-Glucan has only been occasionally determined on CSF, although this is a very recent epidemiologic study. This indirect diagnostic test on the CSF should, therefore, be useful, also in accordance with recent literature results. 1, 9, 12, 22, 25 From a therapeutic point of view, the study confirms that, even in the most recent years, surgical treatment has been used in a minority of cases, both in the forms of IFI-PS (surgery in 33% of cases) and especially in the IFI-CNS (surgery only in 10% of cases). This low percentage of surgery is similar to that of older studies, and it is probably related to various factors such as the presence of disseminated infection, the localisation of the lesion and the high surgical risk related to severe and prolonged thrombocytopenia and immunopression that make these patients at high risk of post-operative infections and bleeding.
1,26
However, compared to older studies, we have observed an improvement in the response to therapy with an ORR of 57% (IFI-CNS ORR = 54%, IFI-PS ORR = 67%), and this is probably due to the availability of drugs, such as VORI and AMB, able to penetrate well into the CNS and PS. In fact, the most commonly used therapeutic agents in our series were AMB as the first-line treatment (followed by VORI) and VORI as second line (followed by AMB). Additionally, a non-negligible percentage of cases (38%) received combination antifungal therapy.
Unfortunately, the median OS of treated cases was short (3.5 months) with a 12-month OS of 32%. Sixty-nine per cent (61/89) of patients died, but it should be emphasised that many patients died from the underlying haematological disease as the primary cause of death. 12, [27] [28] [29] In fact, the attributable mortality was lower (33%) respect to older studies. Another interesting observation that comes from this study is that we did not find significant differences in terms of attributable mortality when comparing IFI-PS with those of CNS. In univariate and multivariate analyses (performed for the larger cohort of patients with IFI-CNS), the factors that were found to affect OS are the response (CR or PR) to antifungal treatment and the status of haematologic disease (not in an advanced stage).
In conclusion, despite the limitations of a retrospective observational study, this is one of the largest recent epidemiological series of IFI-CNS and PS in haematological patients. This study shows that these infectious complications still have a high mortality rate.
However, compared to older epidemiological data, there is a substantial improvement in the response rate to treatment (from less than 20% to more than 50%) and in patient outcome (overall mortality from 100% to 69%). 3, 30, 31 There is likely to be further room for improvement, taking into account the current availability of new antifungal drugs with a broad spectrum of action and with penetrability in PS and CNS, such as isavuconazole and the available possible option of combination antifungal therapy. 
